atazanavir sulfate has been researched along with Coronary Disease in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (80.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dietz, B; Rajagopalan, R; Simpson, KN | 1 |
Margolis, DA; Pakes, GE; Ross, LL; Santiago, L; Shaefer, MS; Sloan, LM; Squires, KE; Wine, BC; Young, B; Zhao, HH | 1 |
Brun, S; Chumney, EC; King, MS; Luo, MP; Simpson, KN | 1 |
Coleman, CI; White, CM | 1 |
Dietz, B; Jones, WJ; Rajagopalan, R; Simpson, KN | 1 |
1 trial(s) available for atazanavir sulfate and Coronary Disease
Article | Year |
---|---|
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Biomarkers; C-Reactive Protein; Coronary Disease; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Inflammation; Interleukin-6; Lamivudine; Lipids; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Pyridines; Risk Assessment; Ritonavir; Treatment Outcome; Young Adult | 2013 |
4 other study(ies) available for atazanavir sulfate and Coronary Disease
Article | Year |
---|---|
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Budgets; CD4 Lymphocyte Count; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; HIV Infections; Humans; Life Expectancy; Lopinavir; Markov Chains; Models, Econometric; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Smoking; United States | 2009 |
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Fees, Pharmaceutical; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Survival Analysis; Survival Rate; Time Factors | 2007 |
A comparison of different protease inhibitors on coronary heart disease risk.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Coronary Disease; HIV Protease Inhibitors; HIV Seropositivity; Humans; Hyperlipidemias; Nelfinavir; Oligopeptides; Pyridines; Risk Factors | 2007 |
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
Topics: Adult; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; France; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Lopinavir; Male; Markov Chains; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Risk Factors; Ritonavir; Spain; Time Factors; United Kingdom | 2007 |